← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 201개
AntibodystaleJanssenApproved

daratumumab (Darzalex, Daratumumab and Hyaluronidase-fihj)

Multiple Myeloma; Newly Diagnosed Multiple Myeloma · Amyloid Light-chain Amyloidosis

#AmyloidLight-chainAmyloidosis#Antibody#Approved#항체#면역항체+4
효능 ORR 0.0%임상시험 22상태 ACTIVE
CGTBiologicstaleNanjing Legend Biotech Co.Phase 2

LCAR-B38M CAR-T Cell (LCAR-B38M CAR-T Cell)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 96.6%임상시험 22상태 DISCONTINUED
AntibodystaleRegeneron PharmaceuticalsPhase 2

Linvoseltamab (Linvoseltamab)

Food Allergy · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+3
임상시험 22상태 RECRUITING
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 1

T cell infusion agent targeting BCMA chimeric antigen receptor (T cell infusion agent targeting BCMA chimeric antigen receptor)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 42.9%임상시험 13상태 ACTIVE
CGTBiologicstaleAsclepius Technology Company Gr…Phase 1

Anti-BCMA CAR-NK Cells (Anti-BCMA CAR-NK Cells)

Multiple Myeloma, Refractory · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 10상태 ACTIVE
AntibodystaleGenentech, Inc.Phase 3

Cevostamab (Cevostamab)

Relapsed or Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+3
임상시험 10상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin-Blmf)

Multiple Myeloma; Multiple Myeloma in Relapse · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 6%임상시험 9상태 RECRUITING
AntibodystalePfizerPhase 2

Elranatamab + lenalidomide + dexamethasone (Elranatamab + lenalidomide + dexamethasone)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 9상태 DISCONTINUED
AntibodystaleGlaxoSmithKlinePhase 2

Feladilimab (Feladilimab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 44%임상시험 9상태 RECRUITING
CGTBiologicstaleNanjing IASO Biotechnology Co.,…Phase 2

Eque-cel (Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection, Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel))

Relapsed/Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 9상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Talazoparib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 0%임상시험 8상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 8상태 ACTIVE
ADCBiologicstaleCanadian Myeloma Research GroupPhase 2

GSK2857916 with Pomalidomide and Dexamethasone (GSK2857916 with Pomalidomide and Dexamethasone)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 7상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin lyophilized powder)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 34%임상시험 6상태 ACTIVE
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR088 (C-CAR088)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 6상태 ACTIVE
ADCBiologicstaleImmunoGen, Inc.Phase 1

IMGN901 (IMGN901)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 0.00%임상시험 6상태 ACTIVE
AntibodystaleJuno Therapeutics, Inc., a Bris…Phase 3

Alnuctamab (Alnuctamab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2
임상시험 5상태 DISCONTINUED
CGTBiologicYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 RECRUITING
CGTBiologicstaleHebei Senlang Biotechnology Inc…Phase 2

BCMA CAR-T (BCMA CAR-T)

Multiple Myeloma, Newly Diagnosed · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 4상태 ACTIVE
CGTBiologicPolina StepenskyPhase 2

HBI0101 CART (HBI0101 CART)

Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed · Systemic Sclerosis (SSc)

#SystemicSclerosisSSc#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 4상태 RECRUITING

3 / 11 페이지

← 이전다음 →